Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis

被引:0
|
作者
Shinn, Grace [1 ]
Berger, Karen [2 ]
Roh, David [3 ]
Doyle, Kevin [3 ]
Boehme, Amelia K. [3 ]
Connolly, Edward Sander [4 ]
Park, Soojin [3 ]
Agarwal, Sachin [3 ]
Claassen, Jan [3 ]
Der-Nigoghossian, Caroline [1 ,5 ]
机构
[1] Columbia Univ, NewYork Presbyterian Hosp, Dept Pharm, Irving Med Ctr, New York, NY USA
[2] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
[3] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurol, Irving Med Ctr, New York, NY USA
[4] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurosurg, Irving Med Ctr, New York, NY USA
[5] Columbia Irving Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, 622 West 168th St, New York, NY 10032 USA
来源
NEUROHOSPITALIST | 2023年 / 13卷 / 03期
关键词
unfractionated heparin; neurocritical care; activated partial thromboplastin time; anti-factor Xa; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; PREVENTION; THROMBOSIS; WEIGHT; VALUES; APTT; CARE;
D O I
10.1177/19418744231159917
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa. Purpose The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation. Methods A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa. Results Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement. Conclusions In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [21] Comparison Between Activated Partial Thromboplastin Time and Anti-Xa Heparin Assays on Patients on Unfractionated Heparin Therapy: Does the Prothrombin Time Matter?
    Pearlman, Eugene
    Singh, Harman
    Willard, Jennifer
    Moore, Darlene
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 : A128 - A128
  • [22] Components of variability of the effect of activated partial thromboplastin time vs. anti-factor Xa on unfractionated heparin dose adjustments
    Guerrero, F.
    Faucher, A.
    Diemert, V
    Voisin, S.
    Sie, P.
    Riviere, Bura A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 380 - 381
  • [23] Determining Cause for Activated Partial Thromboplastin Time and Anti-Factor Xa Discordance in Mechanical Circulatory Support Patients on Heparin; Can Thromboelastogram Help?
    Volod, O.
    Lam, L.
    Robert, C.
    Moriguchi, J.
    Yur, J.
    Garcia, M.
    Zhou, J.
    Wilde, A.
    Czer, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S463 - S463
  • [24] Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience
    Woods, Gary M.
    Stanek, Joseph
    Harrison, Sheilah
    Texter, Karen
    Kerlin, Bryce A.
    Dunn, Amy L.
    Kumar, Riten
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (07) : 576 - +
  • [25] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal
    Kitchen, S.
    Preston, F. E.
    Jennings, I.
    Kitchen, D. P.
    Woods, T. A. L.
    Walker, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2157 - 2158
  • [26] Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin
    Lehman, Christopher M.
    Rettmann, Jonathan A.
    Wilson, Lori W.
    Markewitz, Boaz A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (03) : 416 - 421
  • [27] Xcitement for Xa: Clinical Nurse Specialist as Orchestrator for Implementation of an Organizational Transition From Partial Thromboplastin Time (PTT) to Anti-Factor Xa for Heparin Monitoring
    Howard, Molly
    CLINICAL NURSE SPECIALIST, 2015, 29 (02) : E38 - E38
  • [28] Utility of anti-factor Xa levels in pregnant women receiving low molecular weight heparin prophylaxis
    Allred, Emily
    Quinn, Kristen
    Thorsen, Julia
    Pradarelli, Jason
    Baker, Lisa
    Szabo, Aniko
    Zhao, Shi
    Wassenaar, Timothy
    Kuhlman, Randall
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S280 - S280
  • [29] Basis for Biochemical Discordance Between Activated Partial Thromboplastin Time and Anti-factor Xa in Patients with Continuous Flow Left Ventricular Assist Device on Unfractionated Heparin Infusion
    Yarmohammadi, Hirad
    Feng, Amy J.
    Alraies, Chadi M.
    Thenappan, Thenappan
    Colvin, Monica
    John, Ranjit
    Eckman, Peter
    Pritzker, Marc
    Adatya, Sirtaz
    CIRCULATION, 2014, 130
  • [30] Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
    Tahaineh, Linda
    Edaily, Sahar M.
    Gharaibeh, Shadi F.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 63 - 70